Gerald R. Ford School of Public Policy, University of Michigan.
Altarum Institute.
Milbank Q. 2018 Jun;96(2):272-299. doi: 10.1111/1468-0009.12325.
Policy Points: The Pay for Success (PFS) financing approach has potential for scaling the implementation of evidence-based prevention interventions in Medicaid populations, including a range of multicomponent interventions for childhood asthma that combine home environment risk mitigation with medical case management. Even though this type of intervention is efficacious and cost-saving among high-risk children with asthma, the main challenges for implementation in a PFS context include legal and regulatory barriers to capturing federal Medicaid savings and using them as a source of private investor repayment. Federal-level policy change and guidance are needed to support PFS financing of evidence-based interventions that would reduce expensive acute care among Medicaid enrollees.
Pay for Success has emerged as a potential financing mechanism for innovative and cost-effective prevention programs. In the PFS model, interventions that provide value to the public sector are implemented with financing from private investors who receive a payout from the government only if the metrics identified in a performance-based contract are met. In this nascent field, little has been written about the potential for and challenges of PFS initiatives that produce savings and/or value for Medicaid.
In order to elucidate the basic economics of a PFS intervention in a Medicaid population, we modeled the potential impact of an evidence-based multicomponent childhood asthma intervention among low-income children enrolled in Medicaid in Detroit. We modeled outcomes and a comparative benefit-cost analysis in 3 risk-based target groups: (1) all children with an asthma diagnosis; (2) children with an asthma-related emergency department visit in the past year; and (3) children with an asthma-related hospitalization in the past year. Modeling scenarios for each group produced estimates of potential state and federal Medicaid savings for different types or levels of investment, the time frames for savings, and some overarching challenges.
The PFS economics of a home-based asthma intervention are most viable if it targets children who have already experienced an expensive episode of asthma-related care. In a 7-year demonstration, the overall (undiscounted) modeled potential savings for Group 2 were $1.4 million for the federal Medicaid and $634,000 for the state Medicaid programs, respectively. Targeting children with at least 1 hospitalization in the past year (Group 3) produced estimated potential savings of $2.8 million to federal Medicaid and $1.3 million to state Medicaid. However, current Medicaid rules and regulations pose significant challenges for capturing federal Medicaid savings for PFS payouts.
A multicomponent intervention that provides home remediation and medical case management to high-risk children with asthma has significant potential for PFS financing in urban Medicaid populations. However, there are significant administrative and payment challenges, including the limited ability to capture federal Medicaid savings and to use them as a source of investor repayment. Without some policy reform and clear guidance from the federal government, the financing burden of PFS outcome payments will be on the state Medicaid program or some other state-level funding source.
目的:政策要点:成功付费(PFS)融资方法有可能扩大在医疗补助人群中实施循证预防干预措施的规模,包括一系列结合家庭环境风险缓解和医疗病例管理的儿童哮喘多组分干预措施。尽管这种干预措施在高风险哮喘儿童中具有疗效且节省成本,但在 PFS 背景下实施的主要挑战包括获取联邦医疗补助节省资金并将其用作私人投资者还款来源的法律和监管障碍。需要联邦一级的政策变革和指导,以支持通过成功付费为基于证据的干预措施提供资金,从而减少医疗补助受保人昂贵的急性护理费用。
背景:成功付费已成为创新且具有成本效益的预防计划的潜在融资机制。在 PFS 模式下,为公共部门提供价值的干预措施由私人投资者提供资金,只有在基于绩效的合同中确定的指标得到满足时,政府才会向私人投资者付款。在这个新兴领域,关于为医疗补助产生节省和/或价值的 PFS 计划的潜力和挑战,几乎没有什么可写的。
方法:为了阐明医疗补助人群中 PFS 干预措施的基本经济学,我们对一项基于证据的儿童哮喘多组分干预措施在底特律低收入儿童中进行了建模。我们对 3 个基于风险的目标群体的结果和比较效益成本分析进行了建模:(1)所有有哮喘诊断的儿童;(2)过去一年因哮喘相关急诊就诊的儿童;(3)过去一年因哮喘相关住院治疗的儿童。对每个群体的建模方案产生了不同类型或水平投资的潜在州和联邦医疗补助节省、节省的时间框架以及一些总体挑战的估计。
发现:如果以已经经历过昂贵哮喘相关护理事件的儿童为目标,基于家庭的哮喘干预措施的 PFS 经济学最具可行性。在为期 7 年的示范项目中,针对群体 2 的总体(未贴现)模型潜在节省联邦医疗补助为 140 万美元,州医疗补助为 63.4 万美元。针对过去一年至少有 1 次住院治疗的儿童(群体 3),预计联邦医疗补助潜在节省 280 万美元,州医疗补助潜在节省 130 万美元。然而,当前的医疗补助规则和条例对获取联邦医疗补助节省以支付 PFS 款项构成重大挑战。
结论:为高风险哮喘儿童提供家庭修复和医疗病例管理的多组分干预措施在城市医疗补助人群中具有成功付费融资的巨大潜力。然而,存在重大的行政和支付挑战,包括获取联邦医疗补助节省和将其用作投资者还款来源的能力有限。如果没有一些政策改革和来自联邦政府的明确指导,PFS 结果支付的融资负担将落在州医疗补助计划或其他一些州级资金来源上。